PMID- 25780014
OWN - NLM
STAT- MEDLINE
DCOM- 20150603
LR  - 20191210
IS  - 1943-7722 (Electronic)
IS  - 0002-9173 (Linking)
VI  - 143
IP  - 4
DP  - 2015 Apr
TI  - Clinicopathologic evaluation of MYC expression in primary mediastinal (thymic) 
      large B-cell lymphoma.
PG  - 598-604
LID - 10.1309/AJCPKUG0UQO0HMDJ [doi]
AB  - OBJECTIVES: Based on previous molecular studies, a small fraction of primary 
      mediastinal (thymic) large B-cell lymphoma (PMBL) demonstrates MYC alterations. 
      However, no studies have evaluated MYC protein expression by immunohistochemistry 
      (IHC) with follow-up fluorescence in situ hybridization (FISH) analysis. We aim 
      to evaluate the clinicopathologic importance of MYC IHC expression in PMBL. 
      METHODS: Three pathologists independently evaluated MYC IHC expression in 32 
      cases of PMBL for percent tumor positivity and nuclear intensity. FISH analysis 
      for MYC rearrangement was performed on cases with high MYC IHC expression. 
      Clinical data including treatment, follow-up, and outcome were also reviewed in a 
      subset of cases. RESULTS: Variable MYC protein expression by IHC was detected in 
      30 (94%) of 32 cases of PMBL. One-third of the positive cases (10/30) showed high 
      MYC IHC expression of at least 30% nuclear positivity. FISH analyses for MYC 
      rearrangement on these 10 cases were negative. Review of clinical data on a 
      subset of cases with high and low MYC IHC expression showed no differences in 
      clinical outcome. CONCLUSIONS: MYC protein expression by IHC is present in most 
      PMBLs. Increased MYC protein expression can be seen in one-third of the cases; 
      however, it does not correlate with genetic abnormalities by FISH. There is also 
      no significant impact of MYC protein expression on clinical outcomes.
CI  - Copyright(c) by the American Society for Clinical Pathology.
FAU - Li, K David
AU  - Li KD
AD  - From the Department of Pathology, University of Utah and ARUP Laboratories, Salt 
      Lake City;
FAU - Miles, Rodney
AU  - Miles R
AD  - From the Department of Pathology, University of Utah and ARUP Laboratories, Salt 
      Lake City;
FAU - Tripp, Sheryl R
AU  - Tripp SR
AD  - ARUP Institute for Clinical and Experimental Pathology, Salt Lake City, UT; and.
FAU - Glenn, Martha J
AU  - Glenn MJ
AD  - University of Utah School of Medicine, Salt Lake City.
FAU - Perkins, Sherrie L
AU  - Perkins SL
AD  - From the Department of Pathology, University of Utah and ARUP Laboratories, Salt 
      Lake City;
FAU - Salama, Mohamed
AU  - Salama M
AD  - From the Department of Pathology, University of Utah and ARUP Laboratories, Salt 
      Lake City; salama@path.utah.edu.
LA  - eng
PT  - Evaluation Study
PT  - Journal Article
PL  - England
TA  - Am J Clin Pathol
JT  - American journal of clinical pathology
JID - 0370470
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (MYC protein, human)
RN  - 0 (Proto-Oncogene Proteins c-myc)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Biomarkers, Tumor/*metabolism
MH  - Female
MH  - Humans
MH  - Immunohistochemistry
MH  - In Situ Hybridization, Fluorescence
MH  - Lymphoma, B-Cell/*metabolism/pathology
MH  - Male
MH  - Mediastinal Neoplasms/*metabolism/pathology
MH  - Middle Aged
MH  - Proto-Oncogene Proteins c-myc/*metabolism
MH  - Young Adult
OTO - NOTNLM
OT  - Immunohistochemistry
OT  - MYC
OT  - Primary mediastinal large B-cell lymphoma
EDAT- 2015/03/18 06:00
MHDA- 2015/06/04 06:00
CRDT- 2015/03/18 06:00
PHST- 2015/03/18 06:00 [entrez]
PHST- 2015/03/18 06:00 [pubmed]
PHST- 2015/06/04 06:00 [medline]
AID - 143/4/598 [pii]
AID - 10.1309/AJCPKUG0UQO0HMDJ [doi]
PST - ppublish
SO  - Am J Clin Pathol. 2015 Apr;143(4):598-604. doi: 10.1309/AJCPKUG0UQO0HMDJ.